Western Sydney University, NICM Health Research Institute, Westmead, Australia.
The Professorial Unit, The Melbourne Clinic; Department of Psychiatry, University of Melbourne, Melbourne, Australia.
Can J Psychiatry. 2021 Oct;66(10):849-862. doi: 10.1177/0706743720979917. Epub 2021 Feb 18.
Plant-based medicines have had a long-standing history of use in psychiatric disorders. Highly quantified and standardized extracts or isolates may be termed "phytoceuticals," in a similar way that medicinal nutrients are termed as "nutraceuticals." Over the past 2 decades, several meta-analyses have examined the data for a range of plant-based medicines in the treatment of psychiatric disorders. The aim of this international project is to provide a "meta-review" of this top-tier evidence.
We identified, synthesized, and appraised all available up to date meta-analyses... of randomized controlled trials (RCTs) reporting on the efficacy and effectiveness of individual phytoceuticals across all major psychiatric disorders.
Our systematic search identified 9 relevant meta-analyses of RCTs, with primary analyses including outcome data from 5,927 individuals. Supportive meta-analytic evidence was found for St John's wort for major depressive disorder (MDD); curcumin and saffron for MDD or depression symptoms, and ginkgo for total and negative symptoms in schizophrenia. Kava was not effective in treating diagnosed anxiety disorders. We also provide details on 22 traditional Chinese herbal medicine formulas' meta-analyses (primarily for depression studies), all of which revealed highly significant and large effect sizes. Their methodology, reporting, and potential publication bias were, however, of marked concern. The same caveat was noted for the curcumin, ginkgo, and saffron meta-analyses, which may also have significant publication bias.
More rigorous international studies are required to validate the efficacy of these phytoceuticals before treatment recommendations can be made. In conclusion, the breadth of data tentatively supports several phytoceuticals which may be effective for mental disorders alongside pharmaceutical, psychological therapies, and standard lifestyle recommendations.
植物药在精神疾病的治疗中已有很长的应用历史。高度量化和标准化的提取物或分离物可被称为“植物化学物质”,就像药用营养素被称为“营养药物”一样。在过去的 20 年中,已经有几项荟萃分析研究了一系列植物药治疗精神疾病的疗效数据。本国际项目旨在对这一顶级证据进行“元综述”。
我们确定、综合和评估了所有可用的最新荟萃分析......这些分析报告了针对各种主要精神疾病的个体植物化学物质的疗效和有效性的随机对照试验 (RCT)。
我们的系统搜索确定了 9 项有关 RCT 的荟萃分析,主要分析包括来自 5927 名个体的结果数据。有支持性的荟萃分析证据表明圣约翰草对重度抑郁症(MDD)有效;姜黄素和藏红花对 MDD 或抑郁症状有效,银杏对精神分裂症的总症状和负性症状有效。卡瓦对治疗诊断性焦虑障碍无效。我们还详细介绍了 22 种中药配方的荟萃分析(主要是关于抑郁症的研究),所有这些分析都显示出非常显著和大的效应量。然而,它们的方法学、报告和潜在的发表偏倚令人严重关注。姜黄素、银杏和藏红花的荟萃分析也存在明显的发表偏倚,也存在同样的警告。
在推荐这些植物化学物质进行治疗之前,需要进行更严格的国际研究来验证它们的疗效。总之,这些数据初步支持几种植物化学物质可能对精神障碍有效,与药物治疗、心理治疗和标准生活方式建议一起使用。